ClinicalTrials.Veeva

Menu

Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis

I

Istanbul University

Status

Completed

Conditions

Glomerulonephritis
Focal Segmental Glomerulosclerosis

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease. In this study, our aim is to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.

Full description

Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease worldwide. Numerous studies have been conducted in order to identify the etiology of this debilitating disease. Beyond the etiological research, however, few studies managed to demonstrate the possible predictors of disease progression in patients. Therefore, we aim to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.

Enrollment

86 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with biopsy-proven primary focal segmental glomerulosclerosis.
  • Patients who have a renal biopsy available for reviewing including 8 or more glomeruli.
  • Patients who have been followed-up for at least 6 months or have progressed to primary outcome regardless the duration of follow-up.

Exclusion criteria

  • Patients who have secondary focal segmental glomerulosclerosis attributable to any other condition (e.g., obesity, HIV, relevant drug exposure).
  • Patients who have a genetic mutation or variation creating a tendency for developing focal segmental glomerulosclerosis.
  • Patients who are unwilling or unable to consent.

Trial design

86 participants in 1 patient group

Study Group
Description:
Patients with biopsy-proven primary focal segmental glomerulosclerosis.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems